GW Research Limited
48Patents
48Active
48Granted
59Portfolio score
Filing activity: Jun 10, 2013 → May 19, 2023
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10709671B2 | Use of cannabinoids in the treatment of epilepsy | Performing Operations; Transporting | 45 | Active |
| US10918608B2 | Use of cannabidiol in the treatment of epilepsy | Human Necessities | 45 | Active |
| US10709674B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 44 | Active |
| US10849860B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 44 | Active |
| US10603288B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 44 | Active |
| US10709673B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 44 | Active |
| US10966939B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 43 | Active |
| US11065209B2 | Use of cannabidiol in the treatment of epilepsy | Human Necessities | 39 | Active |
| US11207292B2 | Cannabidiol preparations and its uses | Human Necessities | 38 | Active |
| US11096905B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 38 | Active |
| US11154516B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 38 | Active |
| US11160795B2 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | Human Necessities | 34 | Active |
| US11154517B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 34 | Active |
| US11065227B2 | Use of cannabinoids in the treatment of multiple myeloma | Human Necessities | 34 | Active |
| US10098867B2 | Use of phytocannabinoids in the treatment of ovarian carcinoma | Human Necessities | 32 | Active |
| US10765643B2 | Use of cannabidiol in the treatment of epilepsy | Human Necessities | 31 | Active |
| US10583096B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 30 | Active |
| US11311498B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 29 | Active |
| US11160757B1 | pH dependent release coated microparticle cannabinoid formulations | Human Necessities | 28 | Active |
| US11147776B2 | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy | Human Necessities | 28 | Active |
| US11147783B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 26 | Active |
| US11357741B2 | Use of cannabinoids in the treatment of epilepsy | Performing Operations; Transporting | 26 | Active |
| US11400055B2 | Use of cannabidiol in the treatment of epilepsy | Human Necessities | 25 | Active |
| US11229612B2 | Parenteral formulations | Human Necessities | 25 | Active |
| US11446258B2 | Use of cannabinoids in the treatment of epilepsy | Human Necessities | 24 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.